Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance Find Stocks Now
Close

Acorda Therapeutics Inc (ACORQ)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
0.520 +0.060    +13.04%
23/04 - Closed. Currency in USD ( Disclaimer )
After Hours
0.520
0.000
0.000%
20:56:20 - Delayed Data
  • Volume: 70,030
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 0.460 - 0.640
Type:  Equity
Market:  United States
Acorda 0.520 +0.060 +13.04%

Acorda Company Profile

 
Read the Acorda company profile to learn more about the business and the management team. View Acorda Therapeutics Inc facts about employee data, company products and services, and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

102

Equity Type

ORD

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson’s disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York. On April 1, 2024, Acorda Therapeutics, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.

Contact Information

Address 2 Blue Hill Plaza 3rd Floor
Pearl River, 10965
United States
Phone 914 347 4300
Fax 914 347 4560

Top Executives

Name Age Since Title
Ron Cohen 67 1995 Founder, CEO, President & Director
Sandra Panem 76 1998 Independent Director
John P. Kelley 69 2008 Independent Non-Executive Chairman
Michael S. Beattie - - Member of Scientific Advisory Board
Mark Tuszynski - - Member of Scientific Advisory Board
Melitta Schachner - - Member of Scientific Advisory Board
Carl W. Cotman 83 - Member of Scientific Advisory Board
Jerry Silver - - Member of Scientific Advisory Board
Jacqueline C. Bresnahan - - Member of Scientific Advisory Board
James W. Fawcett - - Member of Scientific Advisory Board
Eugene M. Johnson - - Member of Scientific Advisory Board
Mary B. Bunge - - Member of Scientific Advisory Board
Stephen G. Waxman - - Member of Scientific Advisory Board
Patrick A. Tresco - - Member of Scientific Advisory Board
Peder K. Jensen 68 2011 Independent Director
John W. Varian 63 2022 Independent Director
Thomas M. Burns 49 2023 Independent Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

ACORQ Price Commentary

Write your thoughts about Acorda Therapeutics Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Giampaolo Cau
Giampaolo Cau Oct 20, 2020 12:55
Saved. See Saved Items.
This comment has already been saved in your Saved Items
What’s the news??
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email